Calidi Biotherapeutics, Inc. CLDI
1.13
(0.07)
(5.83%)
as of 25 Sep
- Market cap
- $3.0M
- P/E
- 0.0×
Follow CLDI
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
2.12 | 1.59 | 1.92 | 1.68 |
Net Debt/EBITDA |
2.07 | 1.19 | 1.56 | 0.89 | |
Debt/Assets |
5.68% | 8.70% | 7.79% | 10.56% | |
Debt/Equity |
0.11 | 0.21 | 0.15 | 0.24 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.39 | 1.24 | 0.93 | 1.05 | |
Capex/Depreciation |
(0.06) | (0.07) | (0.01) | (0.08) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(13.91) | (18.87) | (6.40) | (3.10) | |
Cash per Share |
33.83 | 20.83 | 10.29 | 2.88 | |
Shareholders Equity per Share |
23.47 | 13.98 | 7.66 | 2.21 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
23.47 | 13.98 | 7.66 | 2.21 | |
Free Cash Flow |
(4.26) | (5.07) | (4.12) | (4.39) | |
Working Capital |
5.84 | 2.32 | 3.52 | 2.19 | |
Capital Expenditures |
(0.03) | (0.03) | 0.00 | (0.03) | |
Net Current Asset Value |
4.20 | 1.16 | 2.70 | 1.36 | |
| Other line items | |||||
Quick Ratio |
2.00 | 1.42 | 1.73 | 1.26 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(13.82) | (18.76) | (6.39) | (3.07) | |
Capex per Share |
(0.09) | (0.11) | (0.01) | (0.02) | |
Average Payables |
2.36 | 1.34 | 1.05 | 1.08 | |
Average Assets |
10.34 | 11.52 | 12.33 | 8.28 | |
Average Common Equity |
(1.30) | 2.86 | 6.12 | 2.60 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates